MarketResearchReports.Biz is providing you Latest Market Research report of "Alzheimers Disease - Heat Map And Analysis".

1. Alzheimers Disease Market Size, New Study, Overview, Increasing
Growth, Heat Map And Analysis
MarketResearchReports.Biz is providing you Latest Market Research report of "Alzheimers
Disease - Heat Map And Analysis".
Alzheimers disease (AD) is an irreversible, progressive neurodegenerative disease,
characterized by cognitive impairment, memory loss and functional decline. The

2. pathological features of AD comprise a complex set of histopathological changes within
the brain. Symptoms typically begin to first appear in patients in their mid-sixties, and
appear in varying stages. The effects of AD, particularly at an advanced stage, are
devastating to patients and their caregivers, and are associated with significant associated
healthcare costs.
Current treatments focus on sustaining the patient?s cognitive function, managing
behavioural symptoms and slowing down the rate of disease progression. There is
currently no cure for AD, and only six symptomatic treatment therapies have been
approved, of which one (Cognex) is no longer available in the US. The current market
leaders are suboptimal in terms of efficacy, and there is therefore a large unmet need
within AD to develop safer and more efficacious treatments.
There are numerous differences between many of these products due to their mechanisms
of action, and these must be understood fully by companies seeking to position a novel
drug in this market. This tabular heatmap framework, designed to provide an easily
digestible summary of these clinical characteristics, provides detailed information on all

3. late-stage clinical trial results for products in the AD market and Phase III pipeline. These
are split along therapy lines, and are therefore reflective of the treatment algorithm.
Download Sample Copy Of This Report:
http://www.marketresearchreports.biz/sample/sample/915814
All safety and efficacy endpoints reported in these trials are displayed, for both the drug
and placebo groups. In addition, key study characteristics such as the size, composition
and patient segment of the study population are provided. These results are presented in
a visually accessible, color-coded manner in order to maximize ease of use.
The accompanying text provides a detailed analysis of the clinical benchmarks set by the
current market landscape, and the anticipated changes to these benchmarks, and to the
treatment algorithm, as a result of the late-stage pipeline.
Scope

4. What preventative early-stage drugs are generating interest within the AD pipeline?
Will the current AD market landscape ensure that the first drug with a disease-modifying
mechanism of action will become the market leader?
What are the clinical characteristics of currently approved therapies for AD, in terms of
specific safety and efficacy parameters?
What are the key unmet needs in this indication, and which clinical safety and efficacy
parameters are the most closely linked to them?
How will current late-stage molecules affect the market for AChEIs, and are they able to
yield comparable clinical efficacy results?
With three amyloid inhibitors present in the late-stage pipeline, do they have sufficient
differentiating characteristics from previous clinical failures from this class to have an
impact on the market?
Browse More Pharmaceutical Market Research Reports:
http://www.marketresearchreports.biz/category/38
Reasons to buy

5. Understand the current clinical landscape by considering the treatment options available
by drug class.
Visually compare the currently approved treatments available by drug class, based on the
most important efficacy and safety parameters tested in clinical trials.
Assess the current late-stage pipeline, in terms of the likely positioning of each product
and the implications for the clinical landscape at each line of therapy
Understand the relative strengths and weaknesses of the studies used to gather these
data.
Build up a nuanced understanding of the clinical benchmarks set by these products, and
consider how the current late-stage pipeline will affect these benchmarks.
Assess your own pipeline programs in light of these benchmarks in order to optimally
position them and maximize uptake by clinicians.
About us

6. MarketResearchReports.biz is the most comprehensive collection of market
research reports. MarketResearchReports.Biz services are specially designed to
save time and money for our clients. We are a one stop solution for all your
research needs, our main offerings are syndicated research reports, custom
research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.
To View The Top Related News:
http://www.marketresearchreports.biz/articles

7. Contact US:
Office: United States
State Tower
90 State Street, Suite 700
Albany, NY 12207
United States
Toll Free: 866-997-4948
Tel: +1-518-618-1030
E: sales@marketresearchreports.biz